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Abstract
© The  Authors  Journal  compilation  © 2015  Biochemical  Society.  In  the  last  decade,  the
ubiquitin-proteasome system has emerged as a valid  target  for  the development of  novel
therapeutics.  E3  ubiquitin  ligases  are  particularly  attractive  targets  because  they  confer
substrate specificity on the ubiquitin system. CRLs [Cullin-RING (really interesting new gene) E3
ubiquitin ligases] draw particular attention, being the largest family of E3s. The CRLs assemble
into functional  multisubunit  complexes using a repertoire  of  substrate receptors,  adaptors,
Cullin scaffolds and RING-box proteins. Drug discovery targeting CRLs is growing in importance
due to mounting evidence pointing to significant roles of these enzymes in diverse biological
processes  and  human  diseases,  including  cancer,  where  CRLs  and  their  substrates  often
function as tumour suppressors or oncogenes. In the present review, we provide an account of
the assembly and structure of CRL complexes, and outline the current state of the field in terms
of  available  knowledge  of  small-molecule  inhibitors  and  modulators  of  CRL  activity.  A
comprehensive overview of the reported crystal structures of CRL subunits, components and
full-size complexes, alone or with bound small molecules and substrate peptides, is included.
This information is providing increasing opportunities to aid the rational structure-based design
of chemical probes and potential small-molecule therapeutics targeting CRLs.
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